J&J says its Covid vaccine booster shot generated a promising immune response in early trials

Johnson & Johnson said Wednesday a booster shot of its Covid-19 vaccine generated a promising immune response in early stage clinical trials. J&J recipients who received a booster dose of the shot generated virus-fighting antibodies “nine-fold higher” than those seen four weeks after a single dose. While promising, the company’s press release made no mention of the booster shots potential impact on the delta variant or on safety.